Physician profile
Logan M Mcdaneld
NPI 1619001633
$1,552.23
in general payments reported to CMS, 2019-2025
25 companies · $230 in 2025
The $230 reported for 2025 was less than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $224 · 2021: $304 · 2022: $210 · 2023: $115 · 2024: $91.98 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $294.03 | 2019-2023 | |
| Biogen, INC. | $140.41 | 2019-2025 | Tysabri |
| Lilly USA, LLC | $125.95 | 2021-2025 | Kisunla |
| Abbvie INC. | $113.01 | 2021-2022 | |
| Allergan, INC. | $111.79 | 2019-2021 | |
| Emd Serono, INC. | $109.44 | 2019-2023 | Mavenclad |
| Genzyme Corporation | $103.62 | 2019-2023 | |
| Livanova USA, INC. | $91.98 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Teva Pharmaceuticals USA, INC. | $62.71 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $59.44 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $53.09 | 2020-2025 | Ultomiris |
| Ucb, INC. | $44.81 | 2021 | |
| Neurelis, INC. | $41.99 | 2021-2023 | Valtoco |
| Biohaven Pharmaceuticals, INC. | $32.95 | 2021 | |
| Argenx US, INC. | $25.75 | 2023 | Vyvgart |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $23.44 | 2019 | |
| Amgen INC. | $19.12 | 2020 | |
| Avanir Pharmaceuticals, INC. | $17.23 | 2020 | |
| Upsher-Smith Laboratories LLC | $16.44 | 2020 | |
| Genentech USA, INC. | $14.46 | 2019 | |
| Horizon Therapeutics Plc | $14.27 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.34 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.21 | 2022 | |
| Neurocrine Biosciences, INC. | $11.75 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Mcdaneld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.